

# Tobias Maurer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5105611/publications.pdf>

Version: 2024-02-01

178  
papers

11,633  
citations

26630

56  
h-index

30922

102  
g-index

209  
all docs

209  
docs citations

209  
times ranked

8695  
citing authors

#	ARTICLE	IF	CITATIONS
1	PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 7.e1-7.e8.	1.6	6
2	The added value of PSMA PET/MR radiomics for prostate cancer staging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 527-538.	6.4	38
3	Utility of <sup>18</sup> F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1334-1342.	5.0	15
4	[ <sup>68</sup> Ga]Ga-PSMA Versus [ <sup>18</sup> F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2022, 5, 273-282.	5.4	37
5	Robot-assisted Prostate-specific Membrane Antigen- <sup>68</sup> radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study. <i>European Urology</i> , 2022, 82, 97-105.	1.9	37
6	Feasibility of fluorescence imaging at microdosing using a hybrid PSMA tracer during robot-assisted radical prostatectomy in a large animal model. <i>EJNMMI Research</i> , 2022, 12, 14.	2.5	2
7	Validation of <sup>18</sup> F-rhPSMA-7 and <sup>18</sup> F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1809-1814.	5.0	8
8	Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 326-333.	1.9	8
9	Precision surgery: the role of intra-operative real-time image guidance - outcomes from a multidisciplinary European consensus conference.. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 12, 74-80.	1.0	0
10	Positive predictive value and correct detection rate of <sup>18</sup> F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.255661.	5.0	5
11	Final results of the PrAVAC trial: prevention of wound complications following inguinal lymph node dissection in patients with penile cancer using epidermal vacuum-assisted wound closure. <i>World Journal of Urology</i> , 2021, 39, 613-620.	2.2	8
12	Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 469-476.	6.4	119
13	Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?. <i>Asian Journal of Urology</i> , 2021, 8, 248-250.	1.2	0
14	KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 362-369.	3.9	8
15	A DROP-IN Gamma Probe for Robot-assisted Radioguided Surgery of Lymph Nodes During Radical Prostatectomy. <i>European Urology</i> , 2021, 79, 124-132.	1.9	58
16	Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2021, 79, 537-544.	1.9	23
17	First Experience Using <sup>18</sup> F-Fluorobenguane PET Imaging in Patients with Suspected Pheochromocytoma or Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 479-485.	5.0	5
18	Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 294-296.	3.1	3

#	ARTICLE	IF	CITATIONS
19	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. <i>Nature Communications</i> , 2021, 12, 2301.	12.8	159
20	Reply to Francesco Montorsi, Nicola Fossati, Carlo A. Bravi, Giorgio Gandaglia, Nazareno Suardi, and Alberto Briganti's Letter to the Editor re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. <i>Eur Urol</i> 2021;79:537-44. Surgical Treatment of Local Recurrence Following Radical Prostatectomy: Reality or Illusion?. <i>European Urology</i> , 2021, 79, e134.	1.9	0
21	Early prostate cancer recurrence with prostate-specific membrane antigen positron emission tomography positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProStone, NCT04271579). <i>BJU International</i> , 2021, 128, 301-303.	2.5	4
22	Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study. <i>Journal of Urology</i> , 2021, 205, 1663-1670.	0.4	22
23	PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy. <i>EJNMMI Research</i> , 2021, 11, 76.	2.5	12
24	Reply to Fabio C.M. Torricelli and Rafael F. Coelho's Letter to the Editor re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. <i>Eur Urol</i> 2021;79:537-44. <i>European Urology</i> , 2021, 80, e58.	1.9	0
25	Image-guided surgery: from classical techniques to novel aspects and approaches. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 187-189.	0.7	1
26	Contemporary update of SPECT tracers and novelties in radioguided surgery: a perspective based on urology. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 215-228.	0.7	3
27	Implementation of radioguided surgery in prostate cancer. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 202-214.	0.7	1
28	PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 88-91.	5.0	21
29	Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence. <i>European Urology Open Science</i> , 2021, 34, 55-58.	0.4	5
30	Clinical impact of whole-body <sup>68</sup> Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 417-424.	0.7	0
31	Trifecta Outcomes of Partial Nephrectomy in Patients Over 75 Years Old: Analysis of the REal SURGery in Elderly (RESURGE) Group. <i>European Urology Focus</i> , 2020, 6, 982-990.	3.1	20
32	Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). <i>World Journal of Urology</i> , 2020, 38, 151-158.	2.2	23
33	Matched-Pair Comparison of <sup>68</sup> Ga-PSMA-11 PET/CT and <sup>18</sup> F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 51-57.	5.0	161
34	Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction. <i>Journal of Nuclear Medicine</i> , 2020, 61, 234-241.	5.0	42
35	Prostate-Specific Membrane Antigen-Guided Surgery. <i>Journal of Nuclear Medicine</i> , 2020, 61, 6-12.	5.0	31
36	Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?. <i>Bioconjugate Chemistry</i> , 2020, 31, 375-395.	3.6	38

#	ARTICLE	IF	CITATIONS
37	Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e112-e121.	1.9	8
38	Rectal Swabs for Detecting Multidrug Resistant Bacteria Prior to Transrectal Prostate Fusion Biopsy: A Prospective Evaluation of Risk Factor Screening and Microbiologic Findings. <i>Urology</i> , 2020, 136, 127-132.	1.0	4
39	Histologically Confirmed Diagnostic Efficacy of <sup>18</sup> F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 710-715.	5.0	34
40	<sup>18</sup> F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 696-701.	5.0	67
41	A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2968-2977.	6.4	28
42	Pre-test <sup>68</sup> Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy—validation of a prediction model. <i>EJNMMI Research</i> , 2020, 10, 6.	2.5	5
43	Does presence of bone metastases portend worsened prognosis in metastatic renal cell carcinoma? Analysis of the REMARCC (Registry of MetAstatic RCC) database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 655-655.	1.6	2
44	Detection Efficacy of <sup>18</sup> F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 362-368.	5.0	238
45	Robot-assisted laparoscopic surgery using DROP-IN radioguidance: first-in-human translation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 49-53.	6.4	65
46	Recent advances in nuclear and hybrid detection modalities for image-guided surgery. <i>Expert Review of Medical Devices</i> , 2019, 16, 711-734.	2.8	71
47	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7448-7454.	7.0	190
48	Outcomes of Partial and Radical Nephrectomy in Octogenarians – A Multicenter International Study (Resurge). <i>Urology</i> , 2019, 129, 139-145.	1.0	9
49	Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 76, 517-523.	1.9	81
50	A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 47-76.	5.4	140
51	Minimal-Invasive Robot-Assisted Image-Guided Resection of Prostate-Specific Membrane Antigen-Positive Lymph Nodes in Recurrent Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, 580-581.	1.3	41
52	Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 156-157.	5.0	7
53	Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with <sup>177</sup> Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 920-926.	1.9	206
54	Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 159-171.	3.8	62

#	ARTICLE	IF	CITATIONS
55	Practice changing for prostate cancer: a vision of the future. <i>Nature Reviews Urology</i> , 2019, 16, 71-72.	3.8	6
56	<sup>99m</sup> Techneium-based Prostate-specific Membrane Antigen- <sup>68</sup> Ga-radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 75, 659-666.	1.9	195
57	Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery. <i>European Urology Focus</i> , 2019, 5, 50-53.	3.1	52
58	Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection. <i>Clinical Cancer Research</i> , 2018, 24, 2342-2349.	7.0	12
59	Efficacy, Predictive Factors, and Prediction Nomograms for <sup>68</sup> Ga-labeled Prostate-specific Membrane Antigen- <sup>68</sup> Ga-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 656-661.	1.9	129
60	Molecular Markers Increase Precision of the European Association of Urology Non- <sup>68</sup> Ga-Muscle-Invasive Bladder Cancer Progression Risk Groups. <i>Clinical Cancer Research</i> , 2018, 24, 1586-1593.	7.0	79
61	Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands. <i>World Journal of Urology</i> , 2018, 36, 603-608.	2.2	28
62	<sup>68</sup> Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1406-1411.	5.0	106
63	Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. <i>Radiographics</i> , 2018, 38, 200-217.	3.3	262
64	Impact of <sup>68</sup> Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer. <i>Radiation Oncology</i> , 2018, 13, 36.	2.7	15
65	Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis. <i>EJNMMI Research</i> , 2018, 8, 17.	2.5	6
66	Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer. <i>Current Opinion in Urology</i> , 2018, 28, 191-196.	1.8	16
67	Preliminary results on response assessment using <sup>68</sup> Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 602-612.	6.4	107
68	The use of PET/CT in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 4-21.	3.9	70
69	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed mITNM Classification for the Interpretation of PSMA-Ligand PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 469-478.	5.0	372
70	Radio-guided-surgery of a paravertebral paraganglioma using I-123-MIBG. <i>Nuklearmedizin - Nuclear Medicine</i> , 2018, 57, N2-N3.	0.7	2
71	Gallium-68 HBED-CC-PSMA Positron Emission Tomography/Magnetic Resonance Imaging for Prostate Fusion Biopsy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 245-247.	1.9	8
72	One-Stop-Shop Whole-Body <sup>68</sup> Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1850-1856.	5.0	55

#	ARTICLE	IF	CITATIONS
73	Positron emission tomography imaging in urological oncology: Current aspects and developments. International Journal of Urology, 2018, 25, 912-921.	1.0	10
74	MATISSE: Performance in laboratory, results of AIV in Paranal, and first results on sky. , 2018, , .		2
75	Oncological and postoperative outcome of salvage PSMA-radioguided surgery in recurrent prostate cancer.. Journal of Clinical Oncology, 2018, 36, 270-270.	1.6	0
76	Clinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2018, 36, 206-206.	1.6	1
77	Chromogranin A and neuron-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy. BJU International, 2017, 119, 30-37.	2.5	42
78	Bringing clarity or confusion? The role of prostate-specific membrane antigen positron emission/computed tomography for primary staging in prostate cancer. BJU International, 2017, 119, 194-195.	2.5	19
79	Detection Efficacy of Hybrid <sup>68</sup> Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. Journal of Nuclear Medicine, 2017, 58, 1081-1087.	5.0	66
80	Image of the Month. Clinical Nuclear Medicine, 2017, 42, 547-548.	1.3	23
81	<sup>68</sup> Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. Journal of Nuclear Medicine, 2017, 58, 1617-1623.	5.0	111
82	Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 544.e1-544.e10.	1.6	16
83	Value of <sup>111</sup> In-prostate-specific membrane antigen ( <sup>68</sup> Ga-PSMA) radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. BJU International, 2017, 120, 40-47.	2.5	88
84	Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using <sup>68</sup> Ga-PSMA PET/CT. Journal of Nuclear Medicine, 2017, 58, 1632-1637.	5.0	33
85	Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer. Scientific Reports, 2017, 7, 395.	3.3	117
86	<sup>68</sup> Ga-PSMA PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. Prostate, 2017, 77, 920-927.	2.3	89
87	Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2179-2188.	6.4	35
88	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 67S-76S.	5.0	163
89	Patterns of failure after radical prostatectomy in prostate cancer – implications for radiation therapy planning after <sup>68</sup> Ga-PSMA-PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1656-1662.	6.4	51
90	Preconditioned intensity-based prostate registration using statistical deformation models. , 2017, , .		0



#	ARTICLE	IF	CITATIONS
91	<sup>68</sup> Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1949-1955.	5.0	27
92	Radiation Dosimetry for <sup>177</sup> Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2017, 58, 445-450.	5.0	144
93	Preclinical Evaluation and First Patient Application of <sup>99m</sup> Tc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 235-242.	5.0	170
94	Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 344-357.	3.8	3
95	PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?. <i>Theranostics</i> , 2017, 7, 2046-2047.	10.0	12
96	Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. <i>European Urology</i> , 2017, 72, 461-469.	1.9	74
97	<sup>11</sup> C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer. <i>Oncotarget</i> , 2017, 8, 66516-66527.	1.8	25
98	Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 344-357.	3.8	2
99	Biopsie und Targeting. , 2017, , 91-110.		0
100	PSMA-targeted imaging of prostate cancer: evolution of a success story. <i>Asian Journal of Andrology</i> , 2017, 19, 388.	1.6	0
101	PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e549-e552.	1.9	19
102	Integration of <sup>68</sup> Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. <i>Radiation Oncology</i> , 2016, 11, 73.	2.7	79
103	<sup>68</sup> Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases. <i>Clinical Nuclear Medicine</i> , 2016, 41, e261-e262.	1.3	31
104	Biodistribution and radiation dosimetry of <sup>68</sup> Ga-PSMA HBED CC a PSMA specific probe for PET imaging of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1962-1970.	6.4	66
105	Systemic Radioligand Therapy with <sup>177</sup> Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 382-391.	0.4	166
106	<sup>68</sup> Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block Early or Too Early to Draw Conclusions?. <i>European Urology</i> , 2016, 70, 938-940.	1.9	13
107	Inpatient Comparison of <sup>111</sup> In-PSMA I&T SPECT/CT and Hybrid <sup>68</sup> Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, e397-e402.	1.3	45
108	<sup>68</sup> Ga-PSMA PET/MR Showing Intense PSMA Uptake in Nodular Fasciitis Mimicking Prostate Cancer Metastasis. <i>Clinical Nuclear Medicine</i> , 2016, 41, e443-e444.	1.3	19

#	ARTICLE	IF	CITATIONS
109	Value of <sup>68</sup> Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1713-1719.	5.0	213
110	Intravascular volume therapy in adults. <i>European Journal of Anaesthesiology</i> , 2016, 33, 488-521.	1.7	95
111	Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. <i>Cancer Cell</i> , 2016, 30, 27-42.	16.8	486
112	<sup>68</sup> Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. <i>Cancer Imaging</i> , 2016, 16, 14.	2.8	171
113	Comparison of bone scintigraphy and <sup>68</sup> Ga-PSMA PET for skeletal staging in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2114-2121.	6.4	302
114	Evaluation of Computed Tomography for Lymph Node Staging in Bladder Cancer Prior to Radical Cystectomy. <i>Urologia Internationalis</i> , 2016, 96, 51-56.	1.3	45
115	Simultaneous <sup>68</sup> Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. <i>European Urology</i> , 2016, 70, 829-836.	1.9	456
116	Diagnostic Efficacy of <sup>68</sup> Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. <i>Journal of Urology</i> , 2016, 195, 1436-1443.	0.4	659
117	Correlation of tumor-associated macrophages and NK cells with bladder cancer size and T stage in patients with solitary low-grade urothelial carcinoma. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 248-252.	1.9	8
118	<sup>68</sup> Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 367-371.	5.0	112
119	Current use of PSMA- <sup>68</sup> PET in prostate cancer management. <i>Nature Reviews Urology</i> , 2016, 13, 226-235.	3.8	469
120	Imaging for Prostate Cancer Recurrence. <i>European Urology Focus</i> , 2016, 2, 139-150.	3.1	36
121	Intense PSMA-expression using <sup>68</sup> Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 193-194.	6.4	61
122	Prognostic value of computed tomography before radical cystectomy in patients with invasive bladder cancer: imaging predicts survival. <i>World Journal of Urology</i> , 2016, 34, 569-576.	2.2	21
123	Extended versus limited pelvic lymph node dissection during bilateral nerve-sparing radical prostatectomy and its effect on continence and erectile function recovery: long-term results and trifecta rates of a comparative analysis. <i>World Journal of Urology</i> , 2016, 34, 811-820.	2.2	18
124	Intraoperative frozen section monitoring during nerve-sparing radical prostatectomy: evaluation of partial secondary resection of neurovascular bundles and its effect on oncologic and functional outcome. <i>World Journal of Urology</i> , 2016, 34, 229-236.	2.2	12
125	The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. <i>World Journal of Urology</i> , 2016, 34, 181-187.	2.2	73
126	Non-invasive assessment of inter-and inpatient variability of integrin expression in metastasized prostate cancer by PET. <i>Oncotarget</i> , 2016, 7, 28151-28159.	1.8	18



#	ARTICLE	IF	CITATIONS
127	Abstract 428: Hypermethylation of GATA2 is validated as a marker of progression in non-muscle invasive bladder cancer. , 2016, , .		0
128	MP82-10 PSMA-RADIOGUIDED SURGERY: INTRODUCING MOLECULAR SURGERY IN PATIENTS WITH RECURRENT PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.4	1
129	PD32-06 DETECTION RATES OF 68GALLIUM-LABELLED LIGAND OF PSMA PET/CT AND PET/MRI IN 332 CONSECUTIVE PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2015, 193, .	0.4	0
130	Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study. Infectious Agents and Cancer, 2015, 10, 31.	2.6	9
131	Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. , 2015, 3, 26.		206
132	Prostate-specific Membrane Antigenâ€”radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. European Urology, 2015, 68, 530-534.	1.9	192
133	[111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Research, 2015, 5, 68.	2.5	88
134	Clinical prognosticators of survival in patients with urothelial carcinoma of the bladder and lymph node metastases after cystectomy with curative intent. World Journal of Urology, 2015, 33, 813-819.	2.2	6
135	PD32-07 PREOPERATIVE LYMPH NODE STAGING IN INTERMEDIATE TO HIGH-RISK PROSTATE CANCER PATIENTS USING 68GA-HBED-PSMA PET HYBRID IMAGING â€” A PATIENT- AND FIELD-BASED ANALYSIS. Journal of Urology, 2015, 193, .	0.4	6
136	Evaluation of Hybrid <sup>68</sup> Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. Journal of Nuclear Medicine, 2015, 56, 668-674.	5.0	907
137	Multimodal image-guided prostate fusion biopsy based on automatic deformable registration. International Journal of Computer Assisted Radiology and Surgery, 2015, 10, 1997-2007.	2.8	60
138	68Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdominal Imaging, 2015, 40, 1769-1771.	2.0	74
139	PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy.. Journal of Clinical Oncology, 2015, 33, 5023-5023.	1.6	5
140	PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with 68Ga-HBED-PSMA.. Journal of Clinical Oncology, 2015, 33, e16038-e16038.	1.6	3
141	Positron emission tomography/magnetic resonance imaging with <sup>68</sup> Ga-labelled ligand of prostate-specific membrane antigen: Promising novel option in prostate cancer imaging?. International Journal of Urology, 2014, 21, 1286-1288.	1.0	23
142	Use of multifunctional power electronic network controllers in smart distribution systems. , 2014, , .		1
143	Prognostic Value of <sup>11</sup> C-Choline PET/CT and CT for Predicting Survival of Bladder Cancer Patients Treated with Radical Cystectomy. Urologia Internationalis, 2014, 93, 207-213.	1.3	19
144	MP42-18 IMAGING OF RECURRENT PROSTATE CANCER USING 68GALLIUM-LABELLED LIGAND OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN PET/CT AND PET/MRI. Journal of Urology, 2014, 191, .	0.4	0

#	ARTICLE	IF	CITATIONS
145	The method of GFR determination impacts the estimation of cisplatin eligibility in patients with advanced urothelial cancer. <i>World Journal of Urology</i> , 2014, 32, 359-363.	2.2	8
146	Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 694-701.	6.4	79
147	Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. <i>Journal of Hematology and Oncology</i> , 2014, 7, 20.	17.0	38
148	MP42-08 STAGING OF INTERMEDIATE AND HIGH-RISK PROSTATE CANCER USING WHOLE BODY 68GALLIUM-LABELLED LIGAND OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN PET/MRI. <i>Journal of Urology</i> , 2014, 191, .	0.4	2
149	Topography of Lymph Node Metastases in Prostate Cancer Patients Undergoing Radical Prostatectomy and Extended Lymphadenectomy: Results of a Combined Molecular and Histopathologic Mapping Study. <i>European Urology</i> , 2014, 66, 222-229.	1.9	55
150	An Open Source Multimodal Image-Guided Prostate Biopsy Framework. <i>Lecture Notes in Computer Science</i> , 2014, , 1-8.	1.3	3
151	Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1395-1401.	1.6	9
152	PET/MR in prostate cancer: technical aspects and potential diagnostic value. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 79-88.	6.4	49
153	Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 824-831.	6.4	51
154	Detection of circulating tumor cells in different stages of prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 755-763.	2.5	108
155	Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1486-1499.	6.4	107
156	Inguinal lymph node dissection: Epidermal vacuum therapy for prevention of wound complications. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2013, 66, 390-396.	1.0	60
157	Current Staging Procedures in Urinary Bladder Cancer. <i>Diagnostics</i> , 2013, 3, 315-324.	2.6	9
158	Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches. <i>International Journal of Cancer</i> , 2013, 133, 2145-2156.	5.1	28
159	Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2012, 110, E635-40.	2.5	23
160	The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer. <i>Journal of Bone Oncology</i> , 2012, 1, 88-94.	2.4	3
161	680 PREDICTION OF FAVOURABLE OUTCOME AND RATIONAL INDICATION OF DOCETAXEL RECHALLENGE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER. <i>Journal of Urology</i> , 2012, 187, .	0.4	0
162	Diagnostic Efficacy of [11C]Choline Positron Emission Tomography/Computed Tomography Compared With Conventional Computed Tomography in Lymph Node Staging of Patients With Bladder Cancer Prior to Radical Cystectomy. <i>European Urology</i> , 2012, 61, 1031-1038.	1.9	75

#	ARTICLE	IF	CITATIONS
163	Prediction of favorable outcome in a docetaxel rechallenging setting in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2012, 30, 68-68.	1.6	0
164	1925 TUMOR CONFIGURATION OF PROSTATE CANCER (PCA) INFLUENCES THE SENSITIVITY OF [ 11 C]CHOLINE POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY (PET/CT). Journal of Urology, 2011, 185, .	0.4	0
165	1897 LYMPH NODE STAGING OF BLADDER CANCER PATIENTS SCHEDULED FOR RADICAL CYSTECTOMY: CORRELATION OF HISTOPATHOLOGY AND RESULTS OF PRE-OPERATIVE [ 11 C]CHOLINE PET/CT. Journal of Urology, 2011, 185, .	0.4	0
166	Restricted Water Diffusibility as Measured by Diffusion-weighted MR Imaging and Choline Uptake in 11C-Choline PET/CT are Correlated in Pelvic Lymph Nodes in Patients with Prostate Cancer. Molecular Imaging and Biology, 2011, 13, 352-361.	2.6	61
167	Poor efficacy of BEP polychemotherapy in metastatic spermatocytic seminoma. Medical Oncology, 2011, 28, 423-425.	2.5	12
168	The Sensitivity of [11C]Choline PET/CT to Localize Prostate Cancer Depends on the Tumor Configuration. Clinical Cancer Research, 2011, 17, 3751-3759.	7.0	103
169	95 ENHANCING PROTEIN OR PEPTIDE BASED IMMUNOTHERAPY UTILIZING CPG-DNA MEDIATED ANTIGEN SHUTTELING. Journal of Urology, 2010, 183, .	0.4	0
170	Influence of Body Mass Index on Operability, Morbidity and Disease Outcome following Radical Cystectomy. Urologia Internationalis, 2009, 82, 432-439.	1.3	43
171	Multimodal Tumor Therapy in a 31-Year-Old Pregnant Woman with Wilms Tumor. Urologia Internationalis, 2009, 83, 364-367.	1.3	5
172	IMMUNOSTIMULATORY CPG-DNA AND PSA-PEPTIDE VACCINATION ELICITS PROFOUND CYTOTOXIC T CELL RESPONSES. Journal of Urology, 2009, 181, 185-185.	0.4	1
173	780: Effect of Erectile Nerve Reconstruction on Restoration of Erectile Function and Expression of NOS Isoforms. Journal of Urology, 2007, 177, 261-261.	0.4	0
174	Cutting Edge: Toll-Like Receptor 9 Expression Is Not Required for CpG DNA-Aided Cross-Presentation of DNA-Conjugated Antigens but Essential for Cross-Priming of CD8 T Cells. Journal of Immunology, 2003, 170, 2802-2805.	0.8	92
175	CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. European Journal of Immunology, 2002, 32, 2356.	2.9	158
176	Chemical Mechanism Development: Laboratory Studies and Model Applications. Journal of Atmospheric Chemistry, 2002, 42, 323-357.	3.2	22
177	Chemical Mechanism Development: Laboratory Studies and Model Applications. , 2002, , 323-357.		4
178	Kinetic and Product Study of the Atmospheric Photooxidation of 1,4-Dioxane and Its Main Reaction Product Ethylene Glycol Diformate. Journal of Physical Chemistry A, 1999, 103, 5032-5039.	2.5	24